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Brief Communication
Effect of Epigallocatechin-3-Gallate on Graft-Versus-Host Disease
Jaebok Choi,* Matthew L. Cooper,* Edward D. Ziga,†1 Julie Ritchey,* and John F. DiPersio*
*Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
†Division of Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by alloreactive donor 
T-cell-mediated graft-versus-host disease (GvHD). The major polyphenol of green tea, epigallocatechin-3-
gallate (EGCG), is an inhibitor of both DNA methyltransferase 1 (DNMT1) and signal transducer and activator 
of transcription 1 (STAT1), which are essential for induction of GvHD. Thus, in this report, we examine if 
in vivo administration of EGCG mitigates GvHD in several different animal models. While we concede that 
refinement of EGCG treatment might result in GvHD prevention, our results suggest that EGCG treatment 
might not be an effective therapy against GvHD in the clinic.
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Epigallocatechin-3-gallate (EGCG); DNA methyltransferase 1 (DNMT1); Interferon-g receptor signaling; 
Signal transducer and activator of transcription 1 (STAT1)
field of GvHD. Their in vitro proliferation analyses are 
both impressive and compelling. While EGCG-treated 
allogeneic splenocytes result in a significantly improved 
survival according to their most recent report, the benefit 
of EGCG in survival was minimal: median survival of 8 
days (untreated) versus 10 days (EGCG) (5). Moreover, 
all the recipient mice died within 16 days of transplan-
tation, perhaps due to the ineffectiveness of EGCG on 
blocking GvHD or partly because bone marrow cells 
were not transplanted along with splenocytes; thus, it is 
unclear whether the major cause of death was GvHD. In 
addition, the method used (in vitro incubation of puri-
fied donor C57BL/6 splenocytes incubated for 1 h at 
4°C with 200 µM EGCG prior to infusion into Balb/c 
recipients) would be costly and time consuming when 
translated into the clinic. Therefore, in this report, we 
utilized a more clinically preferred method, that is, in 
vivo administration of EGCG into allogeneic recipients, 
to test if EGCG treatment results in reduced GvHD after 
allo-HSCT.
INTRODUCTION
We recently reported that azacitidine (AzaC), a DNA 
methyltransferase 1 (DNMT1) inhibitor, and INCB018424, 
an inhibitor of janus kinase 1 (JAK1)/JAK2, which medi-
ate interferon-g receptor (IFN-g R) signaling via signal 
transducer and activator of transcription 1 (STAT1) phos-
phorylation, mitigate graft-versus-host disease (GvHD) 
while maintaining antileukemia effects (graft-versus-
 leukemia effect or GvL) after allo-hematopoietic stem 
cell transplantation (allo-HSCT) (1,2). The major poly-
phenol of green tea, epigallocatechin-3-gallate (EGCG), 
has been shown to be an inhibitor of both DNMT1 and 
STAT1 (4,8,9,13), thereby being a very attractive poten-
tial therapeutic agent to prevent or treat GvHD after allo-
HSCT.
Hyon and colleagues have proposed that EGCG 
inhibits T-cell activation in vitro (7) and that EGCG-
treated T-cells are less potent at inducing GvHD in vivo 
(5) acting through the blockade of stimulatory receptors. 
The authors’ data have drawn attention to EGCG in the 
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MATERIALS AND METHODS
Mice
All mice (6- to 12-week-old males) were obtained from 
Jackson Laboratory (Bar Harbor, ME, USA). Animal 
study protocols including animal care and euthanasia 
were approved by the Washington University School of 
Medicine Animal Studies Committee.
Cells
Human peripheral blood mononuclear cells (PBMCs) 
were collected in compliance with the protocols out-
lined by the Washington University School of Medicine 
Human Studies Committee and harvested by Ficoll (GE 
Healthcare Bio-science AB, Uppsala, Sweden) gradi-
ent centrifugation. Human pan T-cells were isolated 
from the human PBMCs using Miltenyi microbeads and 
AutoMACS (Miltenyi Biotech, Auburn, CA, USA) (10). 
Mouse pan T-cells were isolated from mouse spleens 
using Miltenyi microbeads and an AutoMACS (Miltenyi 
Biotech) (10).
EGCG
EGCG was purchased from Sigma (St. Louis, MO, 
USA) and suspended in either 10% dimethyl sulfoxide 
(DMSO; Sigma)/phosphate-buffered saline (PBS; Sigma) 
or just PBS, for intraperitoneal injection. See figure leg-
end for additional methods.
RESULTS AND DISCUSSION
We examined whether in vivo administration of EGCG, 
which is more clinically relevant than that of EGCG- 
treated cells, into allo-HSCT recipients reduces GvHD 
after allo-HSCT. Intraperitoneal administration of EGCG 
has been well documented and proven to be an effective 
method of EGCG delivery (3,6,11,12). We tested a fully 
major histocompatibility complex (MHC) mismatched 
(C57BL/6 to Balb/c) (Fig. 1A), a minor mismatched 
(C57BL/6 to C57BL/6x129 F1) (Fig. 1B), and a xenotrans-
plantation model (human T-cells to nonobese diabetic/
severe combined immunodeficient interleukin 2 (IL-2) 
receptor g chain knockout [NOD/SCID/gc KO (NSG)] 
(Fig. 1C). None of the recipients showed improved sur-
vival or a reduction in weight loss, suggesting that EGCG 
when given in the dose and schedule shown was not effec-
tive in ameliorating GvHD in any of these models. We also 
tested whether in vivo administration of EGCG to donor 
mice before harvest of donor T-cells could render the donor 
T-cells inactive at inducing GvHD when transplanted into 
allogeneic recipients (C57BL/6 to C57BL/6x129). Again, 
we observed no decrease of GvHD when compared to 
T-cells from untreated donor mice (Fig. 1D). Although 
we do not exclude a possibility that the doses and tim-
ing used here might not be optimal for EGCG to inhibit 
DNMT1 and STAT1 (our hypothesis) or to mask immu-
nostimulatory receptors (5) and concede that refinement 
of EGCG treatment might result in GvHD prevention, 
our preliminary results do not corroborate or confirm 
those of Kanamune et al. (5) and suggest that the effect of 
EGCG on GvHD is, at best, minimal. In addition, the cur-
rent clinical goal is to prevent GvHD while maintaining 
GvL, which, like GvHD, is also mediated by alloreactive 
donor T-cells. Even though it is conceivable that EGCG-
treated T-cells or direct administration of EGCG to recip-
ients might result in a reduction of GvHD, it remains to 
be determined whether or not it might also abrogate the 
beneficial GvL effect. The “immunocamouflage” of allo-
geneic T-cell receptors by EGCG, as hypothesized by the 
authors (7), is unlikely to result in differential activation 
of donor T-cells by tumor-associated antigens and allo-
antigens on GvHD target organs. Furthermore, based on 
the studies by Kanamune et al. (5), it is likely that EGCG-
treated T-cells would possess less GvL potential since 
their expansion in recipients is highly limited.
In conclusion, although EGCG may be an effective 
inhibitor of both DNMT1 and STAT1, the treatment of 
EGCG after allo-HSCT does not result in prevention or 
reduction of GvHD in four different GvHD models, sug-
gesting that EGCG treatment might not be an effective 
therapy against GvHD in the clinic.
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